Inflammatory Bowel Diseases: Clinical Advances and Emerging Therapies
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".
Deadline for manuscript submissions: 25 July 2025 | Viewed by 698
Special Issue Editor
Interests: pancreatic diseases; inflammatory bowel diseases; esophageal; stomach; intestinal dysfunctions
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Inflammatory bowel disease (IBD) includes mainly ulcerative colitis and Crohn’s disease, which are chronic, progressive diseases.
IBD management is complicated and includes mesalasine, steroids, immunosuppressants, and many new biologic drugs, such as anti-tumor necrosis factor-alpha (TNF-α) agents, anti-integrin agents, anti-interleukin (IL) 12-23 agents, and non-biologic small molecules. The number of available biologics is rapidly growing in recent years and their choice depends on IBD clinical course, previous treatments, including biologics, potential adverse effects, accompanying diseases, and patient’s preferences. Optimal treatment should aim, on the one hand, at clinical remission, endoscopic and histopathologic healing, and prolonged response and, on the other hand, at side effects and complication avoidance.
This Special Issue is dedicated to showcasing the latest clinical advancements in inflammatory bowel disease (IBD). We invite researchers and clinicians to submit their original research articles and reviews that contribute to the understanding, diagnosis, treatment, and management of IBD.
Prof. Dr. Ewa Malecka-Wojciesko
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- inflammatory bowel disease (IBD)
- ulcerative colitis
- Crohn’s disease
- gut inflammation
- bowel perforation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
